Lupuzor (rigerimod): for the treatment of lupus


Lupus is a chronic debilitating incurable inflammatory disease, sometimes fatal, associated with disorders of the immune system.


A look at the science behind Lupuzor´┐Ż and its discovery by Europe's largest Research Institution.


A glance at some of the clinical trial results with Lupuzor showing improvement in the condition of Lupus patients.


The company behind it

ImmuPharma plc is a drug discovery and development group focusing on novel drugs to treat serious medical conditions with a high unmet need.

With operations in the UK, France and Switzerland, ImmuPharma has five lead compounds in development and a strong proprietary pipeline.

A potential treatment for Lupus

Lupus (or SLE) is a debilitating disease whereby the immune system attacks the body's own tissues.
Lupuzor(TM) has a unique mechanism of action, modulating the immune system to potentially halt disease progression.
Following years of testing and clinical trials, the US FDA has given the approval to start the phase III, the final phase of testing.
Lupuzor was discovered by a leading team of scientists at the Centre National de la Recherche Scientifique (CNRS).